P. berghei complete liver stage compound profiling
Profiling MMV portfolio compound activity against the complete P. berghei liver stage.Scope includes compound screenings and portfolio compound testing where data will be delivered within 2 weeks of the end of the test run.
Assays will be ran to detect compounds with activity throughout the P. berghei liver stage. Primary screening will be approved by MMV. After triage, all potential actives will be subjected to full phenotypic profiling at UTSA. Phenotypic profiles will be compared against MMV validation set.